Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNTX-3001
- Development stage
- Phase 1
- Lead developer
- Centrexion Therapeutics
- Modality
- Small Molecules
- Administration
- Intrathecal
01
Overview
CNTX-3001 is a novel, non-opioid, highly potent and highly selective small molecule agonist of the nociceptin receptor (NOPR or OOR), currently in clinical development as an intrathecal therapy for severe chronic pain, including intractable low back pain. Unlike opioids, CNTX-3001 acts specifically on spinal NOPR to induce powerful analgesia while avoiding risk of addiction and behavioral side effects. It is intended primarily for delivery directly to the spinal cord via lumbar puncture or implantable pump, leveraging its favorable solubility properties for local CNS administration. Preclinical studies have shown superior efficacy and side effect profiles compared to intrathecal morphine, and first-in-human Phase 1 trials are underway[1][2][5][7][8].
- Brand names
- CNTX-3001CNTX3001CNTX 3001
- Other names
- CNTX-3001CNTX3001CNTX 3001
02
Targets
NOP (Nociceptin/orphanin FQ peptide receptor)
Beyond the preview
Go deeper on CNTX-3001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNTX-3001.